Furthermore, these authors showed that IDH1-WT primary glioblastomas, at variance with wild IDH1-mutated low-grade gliomas, have a low risk of temozolomide-induced hypermutation [41]. The gene discussed is IDH1; the disease is central nervous system cancer.